Altimmune (ALT) Cash from Investing Activities (2010 - 2026)

Altimmune (ALT) has 17 years of Cash from Investing Activities data on file, last reported at -$3.7 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 27.66% year-over-year to -$3.7 million in Q1 2026; TTM through Mar 2026 was -$131.1 million, a 2272.06% decrease from a year earlier, with the FY2025 full-year figure at -$132.5 million, down 366.68% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$3.7 million, up from -$79.2 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for ALT reached as high as $101.1 million in Q2 2025 and fell as low as -$149.3 million in Q3 2025.
• Historically, Cash from Investing Activities has averaged -$13.2 million across 5 years, with a median of -$3.7 million in 2026.
• Across the five-year window, Cash from Investing Activities jumped 147900.0% in 2023 and tumbled 12553.79% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at $981000.0 in 2022, then plunged by 911.31% to -$8.0 million in 2023, then jumped by 271.28% to $13.6 million in 2024, then tumbled by 680.68% to -$79.2 million in 2025, then soared by 95.34% to -$3.7 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$3.7 million in Q1 2026, -$79.2 million in Q4 2025, and -$149.3 million in Q3 2025.